Vitrolife AB (VITR) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Vitrolife AB SEK 61.91, price SEK 94.75, upside -34.7%, quality 48 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Vitrolife AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range kr 84.83 – kr 550.74 · fair‑value band kr 30.71 – kr 108.02 · the kr 94.75 price screens above the kr 61.91 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Vitrolife in your weekly email
Every Wednesday you see whether Vitrolife is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits.
Show more
Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company also provides eWitness and Labware products, such as dishes, pipettes, tubes, and VitroTemp. The company was incorporated in 1989 and is based in Gothenburg, Sweden.
Stock analysis
Vitrolife AB (VITR) currently trades at kr 94.75, while our model-based Fair Value estimate is kr 61.91, implying the stock looks roughly 53.0% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of kr 78.94 per share, and 3 of the 13 models we run sit above the kr 94.75 price.
Bear case: the Earnings-Based group reads lowest at kr 35.09, and 10 of the 13 models stay below the price. Evidence for this calculation is medium.
Scenario range: kr 30.71 (bear) to kr 108.02 (bull), the price of kr 94.75 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Vitrolife AB reported revenue of 3.4B SEK in FY2025 versus 1.7B SEK in FY2021, a compound +19.6%/yr. Reported net income was −5.0B SEK in FY2025.
Key figures
Market cap 12.8B SEK (≈ $1.3B) · P/S ratio 3.82 · EPS (TTM) kr −37.01 · Dividend yield 1.2% · Net margin −146% · Return on equity −47.3% · Return on assets (EBIT) −1.3% · Operating margin 18.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 37% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −35%, VITR screens richer than that median.
Fair Value models
Bear kr 30.71Fair Value kr 61.91Bull kr 108.02
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.61/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−4.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.5%
Start year 2020 (pandemic). Over 10 years: +16.9% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
33.0% (2019) → 21.7% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+23.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+5.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about +21.2% a year for the price and +3.8% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (92 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 358 stocks
Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score48 · Below median
Fair Value upside−33% · Below median
Profitability
Return on assets3% · Above median
Net margin (TTM)−147% · Bottom 25%
Operating margin (TTM)18% · Top 25%
Growth and dividend
Revenue growth−4% · Below median
Dividend yield (TTM)1.2% · Below median
Balance sheet
Debt / equity0.19× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B0.16× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM)0.37× · Cheapest 25%
P/FCF3.5× · Cheaper than median
EV/EBITDA2.1× · Cheapest 25%
PEG2.02× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 4
FUTURE (revenue growth)0· sector 31
PAST (return on equity)0· sector 7
HEALTH (low debt)91· sector 97
DIVIDEND (yield)23· sector 38
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Vitrolife AB Fair Value". https://www.fairvalue-calculator.com/stock/VITR
Frequently asked questions
Is Vitrolife AB (VITR) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of kr 61.91 versus a price of kr 94.75, about −35% upside (overvalued).
What is the fair value of VITR?
Our model-based fair value for Vitrolife AB is kr 61.91 (as of Sep 23, 2026), built from audited fundamentals. The current price: kr 94.75.
What is the quality score of VITR?
Vitrolife AB has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vitrolife AB (VITR)?
Our model-based price target is the fair value of kr 61.91 (as of Sep 23, 2026) from 13 valuation models. Cautious scenario kr 30.71, optimistic scenario kr 108.02. It is a calculation from audited fundamentals, not an analyst target.
What is the Vitrolife AB stock forecast for 2026?
Our models put fair value at kr 61.91, about −35% upside versus a price of kr 94.75 (overvalued). Cautious scenario kr 30.71, optimistic scenario kr 108.02. The calculation is refreshed regularly with new filings.
What is the revenue of Vitrolife AB (VITR)?
Vitrolife AB reported trailing-twelve-month revenue of about 3.4B SEK (latest available figure, as of Sep 23, 2026).
Does Vitrolife AB pay a dividend?
Vitrolife AB currently shows a dividend yield of about 1.16% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Vitrolife AB (VITR)?
For today's price to be fair in a discounted-cash-flow model, Vitrolife AB would have to grow free cash flow by +23.6 % per year for five years (discount rate 10.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +22.5 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of VITR use?
Our models discount Vitrolife AB at 10.6 %: a base by market capitalisation (large), damped by beta 1.70, country premium for Sweden. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Vitrolife AB that is +23.6 % per year a year over ten years, using the same discount rate (10.6 %) and the same formula as our fair value.
How much growth has Vitrolife AB (VITR) delivered so far?
Over the past 5 years revenue at Vitrolife AB grew +22.5 % a year. The price currently implies +23.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Vitrolife AB (VITR) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Vitrolife AB (+23.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Vitrolife AB (VITR)?
The free-cash-flow yield on the price is 2.84 %: that much free cash flow Vitrolife AB produces per unit of market value. When it exceeds the discount rate of our models (10.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Vitrolife AB (VITR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vitrolife AB it is kr 61.91 per share (as of Sep 23, 2026), against a price of kr 94.75. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is Vitrolife AB stock overvalued or undervalued in 2026?
As of Sep 23, 2026, VITR trades above its calculated fair value: price kr 94.75, fair value kr 61.91, a gap of about −35% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VITR?
No. The price is what the market pays today (kr 94.75); the fair value is what the company's own numbers justify (kr 61.91). For Vitrolife AB the two are kr 32.84 per share apart. That gap is exactly why we show both numbers side by side.
How much is Vitrolife AB worth?
The market values Vitrolife AB at about 12.8B SEK (market capitalisation, as of Sep 23, 2026). Per share that is kr 94.75; our models calculate a fair value of kr 61.91 per share.
What do the bullish and bearish scenarios say about VITR?
Our models span a range for Vitrolife AB: cautious scenario kr 30.71, base kr 61.91, optimistic kr 108.02 per share (as of Sep 23, 2026, price kr 94.75). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of VITR?
The PEG ratio of Vitrolife AB is 2.02 (P/E divided by earnings growth, as of Sep 23, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Vitrolife AB (VITR)?
Balance-sheet figures for Vitrolife AB (as of Sep 23, 2026): return on equity −47.3%, debt of 0.19 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is VITR from its 52-week high?
Vitrolife AB trades at kr 94.75, about 37% below its 52-week high of kr 149.56 and 12% above the low of kr 84.83 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of kr 61.91 is for.
Which stocks are comparable to Vitrolife AB?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vitrolife AB stock attractive at the current price?
The data as of Sep 23, 2026: price kr 94.75, calculated fair value kr 61.91 (−35%), Quality Score 48/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VITR calculated?
We run Vitrolife AB through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 61.91, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Vitrolife AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vitrolife AB (VITR)?
The closing price on Sep 23, 2026 was kr 94.75. Our model-based fair value is kr 61.91, about −35% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vitrolife AB right now?
The model range is unusually wide (kr 30.71 to kr 108.02). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Vitrolife AB
How large is the market capitalisation of Vitrolife AB (VITR)?
The market capitalisation of Vitrolife AB is 12.8B SEK (≈ $1.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vitrolife AB (VITR)?
The price-to-sales ratio of Vitrolife AB is 3.82 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Vitrolife AB (VITR)?
Earnings per share at Vitrolife AB are kr −37.01. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Vitrolife AB (VITR)?
The dividend yield of Vitrolife AB is 1.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Vitrolife AB (VITR)?
The net margin of Vitrolife AB is −146% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Vitrolife AB (VITR)?
The return on equity (ROE) of Vitrolife AB is −47.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vitrolife AB (VITR)?
On an EBIT basis the return on assets of Vitrolife AB is −1.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vitrolife AB (VITR)?
The operating margin of Vitrolife AB is 18.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vitrolife AB (VITR)?
Revenue at Vitrolife AB is growing −4.2% versus a year earlier (3y avg +2.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Vitrolife AB (VITR)?
Earnings per share at Vitrolife AB are growing +0.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Vitrolife AB (VITR) carry?
The net debt of Vitrolife AB is 868M SEK (fiscal year 2025, ≈ 2.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Vitrolife AB in the live analysis
One click puts Vitrolife AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
